Skip to main content

Advertisement

Table 3 Anti-dementia medication

From: Psychotropic and anti-dementia treatment in elderly persons with clinical signs of dementia with Lewy bodies: a cross-sectional study in 40 nursing homes in Sweden

  ATC a Study populationb
N (%)
Dementia diagnosesc P-value Clinical signsd
of DLB
P-value Age groupse P-value
Yes
N (%)
No
N (%)
  0–1||
N (%)
2–4||
N (%)
  ≤85 years
N (%)
≥86 years
N (%)
 
Anti-dementia drugs (All) N06D 192 (33.3) 192 (45.0) 0 (0.0) *** 149 (32.5) 43 (36.8)   104 (43.0) 88 (26.3) ***
ChEI (Any) f N06DA 123 (21.4) 123 (28.8) 0 (0.0) *** 104 (22.7) 19 (16.2)   67 (27.7) 56 (16.8) **
Donepezil N06DA 42 (7.3) 42 (9.8) 0 (0.0) *** 41 (8.9) 1 (0.9) *** 19 (7.9) 23 (6.9)  
Rivastagmin N06DA 31 (5.4) 31 (7.3) 0 (0.0) *** 21 (4.6) 10 (8.5)   25 (10.3) 6 (1.8) ***
Galantamin N06DA 50 (8.7) 50 (11.7) 0 (0.0) *** 42 (9.2) 8 (6.8)   23 (9.5) 27 (8.1)  
Memantin N06DX 100 (17.4) 100 (23.4) 0 (0.0) *** 69 (15.0) 31 (26.5) ** 59 (24.4) 41 (12.3) ***
ChEI & Memantin N06DA N06DX 31 (5.4) 31 (7.3) 0 (0.0) *** 24 (5.2) 7 (6.0)   22 (9.1) 9 (2.7) ***
  1. aAnatomical Therapeutic Chemical (ATC) Classification System
  2. bAll participants: 610 (100%), with registered medical lists for 575 (94%) participants
  3. cDementia diagnoses: there were (N = 440) with a dementia diagnosis and (N = 154)participants without a dementia diagnosis
  4. dClinical signs: visual hallucinations, fluctuating cognition, parkinsonism and REM sleep behaviour disorder
  5. eAge group total 610 (100%): ≤85 years (N = 259) and ≥86 years (N = 351)
  6. fChEI: cholinesterase inhibitor
  7. *P-value < 0.05, **P-value< 0.005, ***P-value < 0.001